Aliqopa
Showing 1 - 23 of 23
Metastatic Castration-resistant Prostate Cancer Trial in San Francisco, Providence (Rucaparib, Copanlisib)
Active, not recruiting
- Metastatic Castration-resistant Prostate Cancer
-
San Francisco, California
- +1 more
Nov 22, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Ibrutinib
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
May 13, 2022
Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)
Active, not recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
-
Duarte, California
- +2 more
Nov 10, 2022
Non Small Cell Lung Cancer Trial in Lexington (Durvalumab, Copanlisib)
Recruiting
- Non Small Cell Lung Cancer
-
Lexington, KentuckyMarkey Cancer Center
Feb 21, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte, New Haven (Copanlisib Hydrochloride,
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Copanlisib Hydrochloride
- Venetoclax
-
Duarte, California
- +1 more
Aug 3, 2022
Lymphoma, Non-Hodgkin Trial in Beijing (Copanlisib (Aliqopa, BAY80-6946))
Completed
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Beijing, ChinaBeijing Cancer Hospital
May 17, 2021
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid System Tumor Trial in Philadelphia (Biopsy,
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Biopsy
- +3 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 5, 2022
Hepatic Insufficiency, Renal Insufficiency Trial in Kiel, Bucuresti (Copanlisib (ALIQOPA, BAY80-6946))
Completed
- Hepatic Insufficiency, Renal Insufficiency
- Copanlisib (ALIQOPA, BAY80-6946)
-
Kiel, Schleswig-Holstein, Germany
- +1 more
Apr 6, 2021
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Canada, United
Recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +5 more
Jan 7, 2023
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States
Recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +7 more
-
Aurora, Colorado
- +7 more
Nov 29, 2022
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +4 more
- Abemaciclib
- +2 more
-
Birmingham, Alabama
- +12 more
Nov 9, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Suspended
- Anatomic Stage III Breast Cancer AJCC v8
- +12 more
- Copanlisib Hydrochloride
- Eribulin Mesylate
-
Gainesville, Florida
- +10 more
Nov 16, 2022
Follicular Lymphoma Trial in Germany (Copanlisib, Obinutuzumab)
Recruiting
- Follicular Lymphoma
-
München, Bavaria, Germany
- +39 more
May 19, 2022
Healthy Volunteers Trial in Austin (Copanlisib (Aliqopa, BAY80-6946), Metformin)
Completed
- Healthy Volunteers
- Copanlisib (Aliqopa, BAY80-6946)
- Metformin
-
Austin, TexasPharmaceutical Product Development (PPD), LLC
Jan 14, 2020
Lymphoma, Non-Hodgkin Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (Aliqopa, BAY80-6946)
-
Birmingham, Alabama
- +100 more
Feb 10, 2022
Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)
Recruiting
- Follicular Lymphoma
- +2 more
- Rituximab
- Copanlisib
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,
Suspended
- Burkitt Lymphoma
- +4 more
- Rituximab
- +6 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Diffuse, Large B-Cell, Lymphoma Trial in Worldwide (Copanlisib (Aliqopa, BAY80-6946))
Completed
- Diffuse, Large B-Cell, Lymphoma
- Copanlisib (Aliqopa, BAY80-6946)
-
Kingswood, New South Wales, Australia
- +31 more
Dec 10, 2018
Tumors Trial in Scottsdale, Pittsburgh, San Antonio (Copanlisib (Aliqopa, BAY80-6946))
Completed
- Neoplasms
- Copanlisib (Aliqopa, BAY80-6946)
-
Scottsdale, Arizona
- +2 more
Oct 5, 2017
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022